Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine

Greta Scapinello; Marco Pizzi; Stefania Vio; Mitja Nabergoj; Andrea Visentin; Annalisa Martines; Laura Bonaldi; Livio Trentin; Gianpietro Semenzato; Francesco Piazza

doi:10.1007/s00277-018-3351-4

Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine

Greta Scapinello, Marco Pizzi, Stefania Vio, Mitja Nabergoj, Andrea Visentin, Annalisa Martines, Laura Bonaldi, Livio Trentin, Gianpietro Semenzato, Francesco Piazza

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2001-2003
Number of pages	3
Journal	Annals of Hematology
Volume	97
Issue number	10
DOIs	https://doi.org/10.1007/s00277-018-3351-4
Publication status	Published - Oct 2018

Keywords

Abnormal Karyotype
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Bendamustine Hydrochloride/administration & dosage
Cell Lineage
Chromosomes, Human, Pair 12
Chromosomes, Human, Pair 14/genetics
Chromosomes, Human, Pair 8/genetics
Disease Progression
Female
Genes, Immunoglobulin
Genes, myc
Humans
Immunoglobulin Heavy Chains/genetics
Lymphocytes/pathology
Lymphoma, B-Cell, Marginal Zone/drug therapy
Middle Aged
Remission Induction
Rituximab/administration & dosage
Splenic Neoplasms/drug therapy
Translocation, Genetic
Trisomy

Access to Document

10.1007/s00277-018-3351-4

Cite this

@article{c8856102ab434744bb99b160c0e9fabe,

title = "Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine",

keywords = "Abnormal Karyotype, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bendamustine Hydrochloride/administration & dosage, Cell Lineage, Chromosomes, Human, Pair 12, Chromosomes, Human, Pair 14/genetics, Chromosomes, Human, Pair 8/genetics, Disease Progression, Female, Genes, Immunoglobulin, Genes, myc, Humans, Immunoglobulin Heavy Chains/genetics, Lymphocytes/pathology, Lymphoma, B-Cell, Marginal Zone/drug therapy, Middle Aged, Remission Induction, Rituximab/administration & dosage, Splenic Neoplasms/drug therapy, Translocation, Genetic, Trisomy",

author = "Greta Scapinello and Marco Pizzi and Stefania Vio and Mitja Nabergoj and Andrea Visentin and Annalisa Martines and Laura Bonaldi and Livio Trentin and Gianpietro Semenzato and Francesco Piazza",

year = "2018",

month = oct,

doi = "10.1007/s00277-018-3351-4",

language = "English",

volume = "97",

pages = "2001--2003",

journal = "Revue d'hématologie",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine

AU - Scapinello, Greta

AU - Pizzi, Marco

AU - Vio, Stefania

AU - Nabergoj, Mitja

AU - Visentin, Andrea

AU - Martines, Annalisa

AU - Bonaldi, Laura

AU - Trentin, Livio

AU - Semenzato, Gianpietro

AU - Piazza, Francesco

PY - 2018/10

Y1 - 2018/10

KW - Abnormal Karyotype

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Bendamustine Hydrochloride/administration & dosage

KW - Cell Lineage

KW - Chromosomes, Human, Pair 12

KW - Chromosomes, Human, Pair 14/genetics

KW - Chromosomes, Human, Pair 8/genetics

KW - Disease Progression

KW - Female

KW - Genes, Immunoglobulin

KW - Genes, myc

KW - Humans

KW - Immunoglobulin Heavy Chains/genetics

KW - Lymphocytes/pathology

KW - Lymphoma, B-Cell, Marginal Zone/drug therapy

KW - Middle Aged

KW - Remission Induction

KW - Rituximab/administration & dosage

KW - Splenic Neoplasms/drug therapy

KW - Translocation, Genetic

KW - Trisomy

U2 - 10.1007/s00277-018-3351-4

DO - 10.1007/s00277-018-3351-4

M3 - Article

C2 - 29728736

VL - 97

SP - 2001

EP - 2003

JO - Revue d'hématologie

JF - Revue d'hématologie

SN - 0939-5555

IS - 10

ER -